Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.94), $0.70 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $87.95 million.

GUIDANCE:

Insmed sees FY2024 revenue of $340-360 million, versus the consensus of $353.2 million.

For earnings history and earnings-related data on Insmed (INSM) click here.